olfactory receptor family 7 subfamily A member 19 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR7A19P profile across patient tissues and cancer cell-line models. OR7A19P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, OR7A19P is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, OR7A19P RNA expression shows 6,936 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight ACC, STAD, and LAML as cancer lineages where OR7A19P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7A19P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7A19P survival associations across molecular data types. OR7A19P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7A19P RNA expression–survival associations across cancer types. High OR7A19P expression shows unfavorable associations in ACC, THCA, LIHC, READ and OV, but favorable associations in LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for OR7A19P RNA expression.
This table summarizes OR7A19P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for OR7A19P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7A19P shows lower tumor expression in KIRC and KICH and higher tumor expression in STAD and PRAD. The STAD box plot shows higher OR7A19P RNA expression in tumor versus normal tissue (log2 FC = +0.101, t-test p = .014).
This table shows molecular features associated with OR7A19P in patient tissues and cancer cell lines. In patient samples, OR7A19P shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set.
